Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 0.35 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30866259 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL30866266 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL10952108 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL9498841 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL13996375 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL2216995 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL25077639 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL2219135 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL8819217 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR | |
| SCHEMBL30114802 | 1.00 | ALDH1A1 (0.62) | ALDH1A1TDP1SMN1; SMN2CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2025-01-30 | — | — | US | disclosed |
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | GILEAD SCIENCES, INC. (US) | 2024-10-15 | — | — | US | disclosed |
| EP-4387977-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2024-06-26 | — | — | EP | disclosed |
| CN-117858881-A | Phospholipid compounds and methods of making and using the same | 吉利德科学公司 | 2024-04-09 | — | — | CN | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023023527-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| WO-2023023527-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | GILEAD SCIENCES, INC. (US) | 2023-02-23 | — | — | WO | disclosed |
| US-5981778-A | Process of producing ether-type thio-phospholipids | SHIONOGI & CO., LTD. (JP) | 1999-11-09 | — | — | US | disclosed |
| US-5760270-A | Process of producing ether-type thio-phospholipids | SHIONOGI & CO., LTD. (JP) | 1998-06-02 | — | — | US | disclosed |
| US-5663405-A | Process of producing ether-type thio-phospholipids | SHIONOGI & CO., LTD. (JP) | 1997-09-02 | — | — | US | disclosed |
| EP-0703237-A1 | Process of producing ether-type thio-phospholipids | SHIONOGI & CO., LTD. (JP) | 1996-03-27 | — | — | EP | disclosed |
| US-5208223-A | Enzyme inhibitors | AMERICAN CYANAMID COMPANY (US) | 1993-05-04 | — | — | US | disclosed |
| US-5144045-A | Treatment of inflammatory related disorders | AMERICAN CYANAMID COMPANY (US) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12116380-B2 | Phospholipid compounds and methods of making and using the same | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 3704/4885TDP1 1808/4885SMN1; SMN2 2018/4885 |
| US-20230212199-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 3704/4885TDP1 1808/4885SMN1; SMN2 2018/4885 |
| US-20250034182-A1 | PHOSPHOLIPID COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | PHOSPHO1, SGMS1, SGMS2 | ALDH1A1 3704/4885TDP1 1808/4885SMN1; SMN2 2018/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.